Program Description:
The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly as the need to slow fibrosis progression and improve long-term outcomes becomes increasingly urgent. While lifestyle and cardiometabolic management remain foundational, newer and emerging pharmacologic options are expanding opportunities to individualize care. Pharmacists need to understand current guidelines to appropriately identify and stage patients, recognize which therapeutic targets are being addressed, and track where therapies are in development to anticipate how practice may change. Key challenges include translating clinical trial end points and eligibility criteria into real-world patient selection and balancing efficacy with adverse event profiles and monitoring requirements. This webinar will equip pharmacists to apply MASH treatment guidelines and deepen knowledge of approved therapies, evaluating late-stage agents and interpreting trial outcomes to translate evidence into real-world patient care. This is the second webinar in the MASLD/MASH curriculum.
Target audience: specialty & health-system pharmacists
Type of activity: Application
Release date: May 13, 2026
Expiration date: May 13, 2027
Time to complete activity: 1 hour
Learner level: Foundational
Fee: Free
Educational
Objectives
At the completion of this activity, participants will be able to:
- Explain MASH, its incidence, risk factors, clinical presentation, and association with poor health outcomes.
- Apply current guideline recommendations for the screening, identification, and treatment of MASLD and MASH.
- Examine the efficacy and safety of currently available therapies for the treatment of MASH.
- Identify the role of the pharmacist in improving care and outcomes for patients with MASLD and MASH.
